Related Experiment Video
Updated: Jan 13, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Small-molecule control of CAR T cells
Eric L Adams1,2,3,4, Andrew C McGovern1,2,3, Victor So1,2,3,4
1UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract:
Chimeric antigen receptor (CAR) T cell therapy is a 'living drug' in which the T cells of patients are genetically engineered with an artificial receptor that directs them to attack diseased cells. CAR T cell therapies have had remarkable impact, curing subsets of patients with previously untreatable, late-stage cancers. However, limitations persist, including severe toxicities, limited survival of engineered cells, and therapeutic resistance. Genetically encoded small-molecule control systems have been developed to address these limitations. They can halt toxicities by eliminating CAR T cells or switching off their function. Furthermore, they can enhance therapy by directly targeting antigens or broadening cell killing ability through cytotoxic pro-drug activation. Small-molecule controllers include protease inhibitors, protein dimerizers, protein degraders, bi-specific adaptors and conditionally activated chemotherapeutics. Here, we outline small-molecule-based control approaches, categorizing them by function and detailing their molecular mechanisms. We emphasize systems in the clinic and highlight emerging applications and unmet areas.
Insights
Chimeric antigen receptor (CAR) T cell therapy uses engineered T cells to fight cancer. Small-molecule control systems enhance CAR T cell therapy by managing toxicities and improving effectiveness against cancer.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Chimeric antigen receptor (CAR) T cell therapy offers a revolutionary approach to treating cancer by genetically modifying patient T cells.
- Despite significant successes in curing some late-stage cancers, CAR T cell therapy faces challenges including toxicity, limited cell survival, and therapeutic resistance.
Purpose of the Study:
- To review and categorize small-molecule-based control systems designed to overcome limitations in CAR T cell therapy.
- To detail the molecular mechanisms of these control systems and highlight their clinical applications and future potential.
Main Methods:
- Categorization of small-molecule controllers based on their functional roles in modulating CAR T cell activity.
- Detailed explanation of the molecular mechanisms underlying various small-molecule control strategies.
- Review of existing clinical applications and emerging research in the field.
Main Results:
- Small-molecule control systems can mitigate CAR T cell toxicities by enabling elimination or functional switching of engineered cells.
- These systems can enhance therapeutic efficacy through direct antigen targeting or pro-drug activation for broader cancer cell killing.
- Examples of small-molecule controllers include protease inhibitors, protein dimerizers, protein degraders, bi-specific adaptors, and conditionally activated chemotherapeutics.
Conclusions:
- Small-molecule control systems represent a critical advancement in refining CAR T cell therapy.
- These systems offer versatile strategies to enhance safety, improve persistence, and broaden the applicability of CAR T cell therapies in oncology.
- Further development and clinical translation of these control mechanisms hold significant promise for improving patient outcomes in cancer treatment.
Related Concept Videos
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Tumor Immunotherapy